By 2030, will the FDA approve any drug in combination with a checkpoint blockade therapy that substantially reduces immune escape?
GeopoliticsOne-OffHealth & Medicine3y
Manifold MarketsNo KYCVerified resolution dataFairly calibratedData quality warningSource data degraded
Data as of Oct 26, 2026, 6:50 AM UTC · policy pm-quality-4
Current community forecastYes 53.5%
Forecasters
5
Question type
binary
Methodology
Play-money forecasting platform
Source type
Forecast
Market data
Updated 1 hour ago
LaggingNov 18, 22, 2:41 AM UTCJan 1, 30, 8:00 AM UTC
Trends
Rules
Checkpoint blockade therapy (also called immune checkpoint inhibitors) is an cancer therapy that works (roughly speaking) by preventing the cancer from disabling the immune system.
- There's a list of major immune checkpoint inhibitors here: https://en.wikipedia.org/wiki/Checkpoint_inhibitor
- A common issue with this kind of therapy is immune escape: the cancer mutates and escapes from the immune system in some other way, which makes the drug much less effective or even useless.
- You can read an overview of the topic here: https://sci-hub.se/10.1093/annonc/mdw217
- This market resolves YES if any combination therapy is approved that:
- Reduces immune escape by >= 10 percentage points over the course of two years according to any metric in an associated publication.
